TILT-321

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameTILT-321

Drug Alias NameAd5/3-E2F-d24-aMUC1aCD3TILT-321

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vectorBiologics > T cell engagers +[4]

Mechanisms of ActionAnti-MUC1CD3 T-cell engagers

TargetsMucin-1T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFinland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTilt Biotherapeutics Ltd University Of Helsinki

China Registration ClassN/A

Develop Information

Active CompaniesTilt Biotherapeutics Ltd University Of Helsinki

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A